Induction of Immunological Tolerance for Gene Therapy
Induction of Immunological Tolerance for Gene Therapy
批准号:
7194063
负责人:
JAMES C. ZIMRING
金额:
$19.13万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-02-01 至 2009-01-31
关键词:
AddressAnimal ModelAntigen-Presenting CellsAntigensApplications GrantsAreaBiological ModelsCD8B1 geneCell physiologyCellsChickensClinical TrialsComplementary DNAConditionDataDevelopmentEngineeringFunding MechanismsGenerationsGenesGenetic MaterialsGoalsGrantHemophilia AHistocompatibility Antigens Class IHumanImmuneImmune responseImmune systemIn VitroInvestigationKnowledgeLeadLettersMHC Class I GenesMethodsModelingMusMutationNumbersOvalbuminPhysiologicalPurposeResearchResearch DesignResearch PersonnelSystemT-LymphocyteTechnologyTestingTissuesTransduction GeneTransgenesbasegene therapyin vivonovelprogramsresearch studyresponsetherapeutic genetooltranslational study
中文摘要
描述(由申请人提供):
基因治疗的理论基础是通过将功能基因导入接受者的组织来纠正遗传缺陷。现在有各种技术可以越来越有效地将遗传物质引入基因治疗接受者。然而,受体免疫系统对转导基因的排斥仍然是稳定长期表达的持久障碍。在这项资助中,我们提出了一种策略,通过利用基于否决细胞的方法来选择性地诱导对治疗基因的免疫耐受,从而绕过免疫排斥的障碍。CDS*否决权细胞起缺失抗原提呈细胞的作用,可清除识别CDS*否决权细胞MHC I类递呈抗原的T细胞。因此,要设计一种能够删除能够识别治疗性基因产物的T细胞的接受者否决权细胞,必须从接受者那里产生CD8+否决权细胞,并将治疗性基因插入CDS*否决权细胞。这项资助申请的中心假设是,受者来源的CDS*否决权细胞与治疗性基因一起转导,可用于选择性地耐受接受者的免疫系统对治疗性基因。通过这种方式,基于免疫的排斥转导基因将被消除,作为基因治疗的障碍。特定目的1-表达转导基因的受体来源的CDS*否决权细胞的生成。为此,我们将优化所需的条件,以快速有效地从受体组织中分离大量转导基因的CD8+否决权细胞。为了进行尽可能复杂的分析,我们将利用一个转基因模型,其中存在大量工具来分析免疫反应(鸡卵清蛋白(OVA))。这一优化将包括最大限度地扩大CDS*否决权细胞以优化产量,并最大限度地提高MHC I类分子上的基因转导、表达和呈现的效率。特定目的2-评估基因治疗转导的CDS*否决权细胞诱导对治疗基因的抗原性耐受的能力。为此,我们将测试表达CDS*VOTO细胞的受体来源的OVA细胞耐受抗OVA T细胞反应的能力。这将通过在体外研究OVA特异的否决权活性和进行体内耐受性实验来实现。通过将更多的体外还原系统与更具生理学的体内系统相结合,我们将能够评估机械决定和生理效果。
英文摘要
DESCRIPTION (provided by applicant):
The theoretical basis of gene therapy is the correction of a genetic defect through the transduction of a functional gene into the tissues of the recipient. A variety of technologies now exist for the increasingly efficient introduction of genetic material into a gene therapy recipient. However, rejection of the transduced gene by the recipient immune system remains a persistent obstacle to stable long-term expression. In this grant, we propose a strategy that circumvents the obstacle of immune rejection by utilizing a veto cell based approach to selectively induce immunological tolerance to the therapeutic gene. CDS* veto cells function as deletional antigen presenting cells, which eliminate T cells that recognize antigens presented by the MHC class I of the CDS* veto cell. Thus, to engineer a recipient veto cell that will delete T cells capable of recognizing the product of a therapeutic gene, one must both generate CD8+ veto cells from the recipient and insert the therapeutic gene into the CDS* veto cells. The central hypothesis of this grant application is that recipient derived CDS* veto cells, which are transduced with the therapeutic gene, can be used to selectively tolerize the recipient immune system to the therapeutic gene. In this way, immune based rejection of the transduced gene will be eliminated as an obstacle to gene therapy. Specific Aim 1- Generation of recipient derived CDS* veto cells expressing a transduced gene. In this aim, we will optimize the conditions required to rapidly and efficiently isolate large numbers of gene transduced CD8+ veto cells from recipient tissues. To perform as sophisticated an analysis as possible, we will utilize a model transgene for which a large arsenal of tools exist to analyze immune responses (chicken ovalbumin (OVA)). This optimization will include maximizing expansion of CDS* veto cells to optimize yields and maximizing the efficiency of gene transduction, expression and presentation on MHC class I molecules. Specific Aim 2- Assess the ability of gene therapy transduced CDS* veto cells to induce antigenspecific tolerance to the therapeutic gene. In this aim, we will test the ability of the recipient derived OVA expressing CDS* veto cells to tolerize anti- OVA T cell responses. This will be accomplished by both studying OVA specific veto activity in vitro and by performing in vivo tolerization experiments. By combining the more reductionist in vitro systems with the more physiological in vivo systems, we will be able to assess both mechanistic determinations and physiological efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion. Project 1
-
批准号:10711668
-
项目类别:
-
资助金额:$40.29万
-
财政年份:2023
-
负责人:JAMES C. ZIMRING
-
依托单位:
Basic and Translational Mechanisms of Alloimmunization to RBC Transfusion
-
批准号:10711666
-
项目类别:
-
资助金额:$243.08万
-
财政年份:2023
-
负责人:JAMES C. ZIMRING
-
依托单位:
Immunobiology of Alloimmunization by Platelet Transfusion
-
批准号:10418747
-
项目类别:
-
资助金额:$55.06万
-
财政年份:2019
-
负责人:JAMES C. ZIMRING
-
依托单位:
Immunobiology of Alloimmunization by Platelet Transfusion
-
批准号:10192810
-
项目类别:
-
资助金额:$55.06万
-
财政年份:2019
-
负责人:JAMES C. ZIMRING
-
依托单位:
Immunobiology of Transfusion
-
批准号:10018077
-
项目类别:
-
资助金额:$246.85万
-
财政年份:2017
-
负责人:JAMES C. ZIMRING
-
依托单位:
Immunobiology of Transfusion
-
批准号:10192789
-
项目类别:
-
资助金额:$246.56万
-
财政年份:2017
-
负责人:JAMES C. ZIMRING
-
依托单位:
Administrative Core
-
批准号:10192790
-
项目类别:
-
资助金额:$24.9万
-
财政年份:2017
-
负责人:JAMES C. ZIMRING
-
依托单位:
Immunobiology of Transfusion
-
批准号:9360036
-
项目类别:
-
资助金额:$237.4万
-
财政年份:2017
-
负责人:JAMES C. ZIMRING
-
依托单位:
Antibody Mediated Immune Regulation
-
批准号:10192792
-
项目类别:
-
资助金额:$53.49万
-
财政年份:2017
-
负责人:JAMES C. ZIMRING
-
依托单位:
Prevention of Platelet Alloimmunization by Costimulatory Blockade
-
批准号:8783253
-
项目类别:
-
资助金额:$46.75万
-
财政年份:2014
-
负责人:JAMES C. ZIMRING
-
依托单位:
Prevention of Platelet Alloimmunization by Costimulatory Blockade
-
批准号:9265120
-
项目类别:
-
资助金额:$46.75万
-
财政年份:2014
-
负责人:JAMES C. ZIMRING
-
依托单位:
Pathobiology of Incompatible transfusion
-
批准号:9058138
-
项目类别:
-
资助金额:$46.75万
-
财政年份:2013
-
负责人:JAMES C. ZIMRING
-
依托单位:
Pathobiology of Incompatible transfusion
-
批准号:8700493
-
项目类别:
-
资助金额:$45.82万
-
财政年份:2013
-
负责人:JAMES C. ZIMRING
-
依托单位:
Pathobiology of Incompatible transfusion
-
批准号:9265132
-
项目类别:
-
资助金额:$46.75万
-
财政年份:2013
-
负责人:JAMES C. ZIMRING
-
依托单位:
Pathobiology of Incompatible transfusion
-
批准号:8451766
-
项目类别:
-
资助金额:$23.38万
-
财政年份:2013
-
负责人:JAMES C. ZIMRING
-
依托单位:
Platelet Transfusion Induced Transplant Rejection Across mHA barriers.
-
批准号:8207221
-
项目类别:
-
资助金额:$15.74万
-
财政年份:2011
-
负责人:JAMES C. ZIMRING
-
依托单位:
Platelet Transfusion Induced Transplant Rejection Across mHA barriers.
-
批准号:8020527
-
项目类别:
-
资助金额:$38.54万
-
财政年份:2011
-
负责人:JAMES C. ZIMRING
-
依托单位:
Platelet Transfusion Induced Transplant Rejection Across mHA barriers.
-
批准号:8788292
-
项目类别:
-
资助金额:$46.05万
-
财政年份:2011
-
负责人:JAMES C. ZIMRING
-
依托单位:
Platelet Transfusion Induced Transplant Rejection Across mHA barriers.
-
批准号:8402587
-
项目类别:
-
资助金额:$44.51万
-
财政年份:2011
-
负责人:JAMES C. ZIMRING
-
依托单位:
Platelet Transfusion Induced Transplant Rejection Across mHA barriers.
-
批准号:8601877
-
项目类别:
-
资助金额:$45.82万
-
财政年份:2011
-
负责人:JAMES C. ZIMRING
-
依托单位:
海外基金